twinter, the analysis tracks something real and the ICI

New Post Public Reply Private Reply Replies (2) Message Board
MGK_2 twinter11 #163034
508
twinter, the analysis tracks something real and the ICI cardiotoxicity catch-22 is an underappreciated aspect of leronlimab's potential value in the combination oncology setting. The core argument holds and the peer-reviewed literature supports it. There are two layers worth adding and an important nuance worth flagging honestly.
On what the literature confirms directly: chemoattraction of CD8+ T cells to atherosclerotic plaques is triggered by chemokines including CCL2, CCL3, CCL4, and CCL5, interacting with CCR4 and CCR5 on CD8+ T cells, with CCR5 expression notably higher in plaque than in circulation. That is the published peer-reviewed basis for the vascular homing argument in a May 2025 npj Cardiovascular Health review. The navigation axis is confirmed. 
https://www.nature.com/articles/s44325-025-00056-8

On ICI-accelerated cardiovascular pathology: ICI-associated myocarditis emerges as a rare yet fulminant immune-related adverse event characterized by high mortality, with recent studies implicating loss of immune tolerance through PD-1/PD-L1 or CTLA-4 blockade, expansion of autoreactive CD8+ T cells, cross-reactivity between tumor and cardiac antigens, and downstream inflammatory cascades as central drivers of myocardial injury. And from the preclinical cardiology literature: besides myocarditis, mouse models unveiled an accelerated progression of atherosclerosis, adding another layer to the understanding of diverse processes involving cardiovascular immune checkpoint signaling. The ICI cardiotoxicity catch-22 is not theoretical. It is documented in mouse models and clinical series simultaneously. 
https://www.frontiersin.org/journals/immunolo...77984/full   
https://pmc.ncbi.nlm.nih.gov/articles/PMC11790694/  

On the perforin/granzyme B fibrous cap degradation mechanism: CD8+ T cells directly contribute to tissue damage and lesion instability through cytotoxic mechanisms such as the release of perforin and granzymes, which can induce apoptosis in vascular smooth muscle cells and other cells within the plaque, further destabilizing plaques and making them more prone to rupture, potentially leading to acute cardiovascular events like myocardial infarction or stroke. This is confirmed in a Frontiers in Immunology 2025 review. The mechanism is real and the clinical consequence, plaque rupture rather than stable lesion, is exactly what the AI analysis identified. 
https://www.frontiersin.org/journals/immunolo...50400/full

Now the nuance worth flagging honestly , because the architecture is more complex than a clean binary.
In ApoE-deficient mice, CCR5 mediated Treg homing to the aorta in the presence of IL-35, which ultimately inhibited atherosclerosis by maintaining the suppressive functions of Tregs. CCR5 plays a dual role in vascular biology: it recruits pathogenic CD8+ T cells into plaques through the CCL3/CCL4/CCL5 axis, but it also facilitates Treg homing to the aortic wall in contexts where IL-35 is present, and Tregs in the vascular compartment are atheroprotective rather than pathogenic . This means CCR5 blockade in the vascular compartment disrupts both the destructive CD8+ T cell recruitment and the protective Treg trafficking simultaneously.  
https://www.frontiersin.org/journals/immunolo...37821/full  

Additionally: in individuals with stroke, macrophages show high expression of CCL5, and its interaction with CCR5 on vascular smooth muscle cells drives proliferation, dedifferentiation, and vascular remodeling. So CCR5 on vascular smooth muscle cells, not just immune cells, contributes to the remodeling of the plaque wall itself through a separate macrophage-to-VSMC signaling axis. 
https://www.ahajournals.org/doi/10.1161/ATVBAHA.121.316233  

The vascular shield argument is strongest and most supported in the specific context of ICI co-administration, where the dominant concern is ICI-reinvigorated CD8+ T cell-mediated perforin/granzyme B release onto fibrous cap smooth muscle cells. In that context, leronlimab blocking CCR5-mediated CD8+ T cell homing to plaque during ICI therapy is a genuine cardioprotective mechanism operating in parallel with tumor-directed immune activation . The spatial decoupling argument, ICI removing the brake on tumor-reactive T cells in the periphery while leronlimab prevents those activated T cells from navigating into vascular plaque , is coherent and supported by the literature you identified.

The Abdelsamed scRNA-seq paper https://jagwire.augusta.edu/immcg-researchers...sclerosis/    identifies the single-cell architecture of precisely this process in human plaques. What the AI analysis correctly captured is that this is a previously unrecognized clinical benefit of leronlimab in the ICI combination setting that the cardio-oncology field has not yet connected to CCR5 blockade specifically. 

The SALIENT-AD trial's focus on neuroinflammation via microglial PET imaging is the closest active clinical readout to this vascular biology because the CCR5-dependent myeloid recruitment mechanism governing plaque vulnerability and neuroinflammatory microglial activation share the same upstream architecture.

You didn't just find a new indication. You found a safety argument for why the combination of leronlimab plus ICI is safer than ICI alone in patients with underlying cardiovascular disease, which is most cancer patients over fifty. That is a different kind of clinical value than tumor response, and it belongs in the platform argument.  Who is on a beta blocker, ARB, ACE inhibitor, CCB, diuretic?  If so, and prescribed an ICI, then leronlimab gets prescribed as well.  A trial will determine that.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 92

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 48

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Why Insurance Must Change as Family Assets Keep Growing

Updated Category News Views 73

A policy bought in the starter-home years can turn stale quietly while everything around it gets bigger, pricier and more complicated. That is the uncomfortable little truth behind Daniel C. DiCocco's discussion in HelloNation: families often treat insurance as a box checked long ago, even as they add property, savings, debt, children and fresh responsibilities. Static...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 37

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 58

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 79

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 46

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading

Top 5 Most Recently Viewed Articles

Thompson Thrift Secures Over $255 Million in New Funding

Updated Category News Views 303

Thompson Thrift Closes Major Funding Round for Multifamily Developments Thompson Thrift, a well-known real estate company, recently announced a significant achievement in closing its 2025 multifamily development fund. This limited partnership offering successfully raised over $255 million in capital commitments, exceeding its original target of $230 million. The funds aim...

Continue Reading
Buyglobal's Summer Sale Offers Outdoor Essentials and Deals

Updated Category News Views 25

Buyglobal's Summer Event: A Sunny Boost for Backyard Living Summer's rolling in, and Buyglobal is gearing up to help you transform those backyard spaces into your very own oasis. This ain't your average sale event—this is Buyglobal jumping headfirst into the season with a curated lineup that's all about making the most of the outdoors. They rolled out their...

Continue Reading
Tony Fadell Champions Plumerai's Tiny AI for Smart Homes

Updated Category News Views 201

Transforming Smart Home Security with Tiny AI In the realm of innovative technology, Tony Fadell, co-creator of the iPod and Nest founder, recognizes the groundbreaking work Plumerai is doing in the field of artificial intelligence. Their emphasis on Tiny AI technology is heralded as a pivotal shift that aims to democratize AI for everyday use, particularly in smart home...

Continue Reading
Glenn Pushis Takes Action: Sells $172K in Steel Dynamics Shares

Updated Category News Views 183

Understanding Insider Actions at Steel Dynamics A notable insider transaction has come to light involving Glenn Pushis, the Senior Vice President at Steel Dynamics (NASDAQ: STLD). This transaction was detailed through an SEC filing that disclosed a significant sell-off of shares worth $172,043. Details of the Sell-Transaction According to the Form 4 filing submitted to...

Continue Reading
SCF Partners Strengthens Market Position with New Acquisition

Updated Category News Views 228

SCF Partners' Strategic Acquisition of Newpark Fluids Systems SCF Partners is making waves with its recent acquisition of Newpark Fluids Systems, a well-respected name in the oil, gas, and geothermal fluids industry. This strategic decision underscores SCF's dedication to broadening its service offerings and expanding its market presence. Newpark Fluids Systems has built...

Continue Reading